QC
ARRY

QCM Cayman’s Array Biopharma Inc ARRY Stock Holding History

QCM Cayman’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,332
Closed -$207K – 187
2018
Q2 		$207K Buy
+12,332
New +$196K 0.96% 56
2015
Q2 		– Sell
-14,892
Closed -$110K – 274
2015
Q1 		$110K Buy
+14,892
New +$106K 0.06% 184

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

QCM Cayman's ARRY Position: Q3 2018 in Review

QCM Cayman sold out of Array Biopharma Inc (ARRY) in Q3 2018, closing a stake of 12,332 shares — an estimated $207K sold.

QCM Cayman first reported a position in ARRY in Q1 2015 and held it in 2 quarters. The position peaked at $207K in Q2 2018. 208 funds tracked by Wall St. Rank hold ARRY as of Q3 2018.

  • QCM Cayman reported no remaining Array Biopharma Inc position as of Q3 2018 after selling out during the quarter.
  • QCM Cayman sold 12,332 Array Biopharma Inc shares in Q3 2018, an estimated $207K.
  • QCM Cayman first reported a position in Array Biopharma Inc in Q1 2015 and held it in 2 quarters.
  • QCM Cayman's Array Biopharma Inc position peaked at $207K in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2018.

Based on QCM Cayman's 13F filing for Q3 2018, filed 14 Nov 2018.